Aclaris Therapeutics Inc (NASDAQ:ACRS) traded at $3.02 at close of the session on Monday, December 16 and made a downward move of -6.21% on its previous day’s price.
Looking at the stock we see that its previous close was $3.22 and the beta (5Y monthly) reads 0.116 with the day’s price range being $2.99 – $3.2675. In terms of its 52-week price range, ACRS has a high of $5.17 and a low of $0.80. The company’s stock has gained about 38.53% over that past 30 days.
Aclaris Therapeutics Inc has a market cap of $212.43 million and is expected to release its quarterly earnings report in January.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at 6.23M, with a low of 645k and a high of 31.1M. The median projection represents growth adding up to -64.55% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 16.31M, or -47.81% down from figures reported last year.
On the other hand, looking at the outlook for the ACRS stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 100% Buy.
Based on estimates by 4 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Aclaris Therapeutics Inc (ACRS) stock as a Hold, while 3 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 1 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is -19.71% off its SMA20 and 19.57% from its 50-day simple moving average. The RSI (14) is pointing at 45.40 while the volatility over the past week is 8.94% and jumps to 13.73% over the past one month. The beta value is 0.47, while the average true range (ATR) is currently pointing at 0.36. The average price target for the stock over the next 12 months is $7, with the estimates having a low of $3 and a high of $8. These price ends are 0.66% and -164.9% off the current price level respectively, although investors could be excited at the prospect of a -131.79% if the ACRS share price touches on the median price of $7.
Coming back to Aclaris Therapeutics Inc (NASDAQ:ACRS), we note that the average 3-month trading volume was 2.27 million, while that of the preceding 10-day period stands at 0.87 million. Current shares outstanding are 71.42 million.
The insiders hold 16.15% of the company’s shares while institutions hold 75.64%. The data shows that short shares as of 2024-11-29, stood at 2.48 million at a short ratio of 0.47. This represents a 414.00 short interest in shares outstanding on 2024-11-29. Shares short rose in November from the previous month at 2.41 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 187.62% up in year-to-date price movement.
